SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Iridium Communications entered into a definitive Agreement and Plan of Merger with Rocket Lab Corporation on June 28, 2026, whereby Rocket Lab will acquire all outstanding shares of Iridium common stock for $54 per share ($27 cash plus stock consideration), representing an enterprise value of approximately $8.0 billion. The transaction is expected to close in mid-2027, subject to stockholder approval and regulatory clearance.
View raw filing on EDGAR →Terra Property Trust announced final results of a registered exchange offer in which holders of 6.00% Senior Notes due June 30, 2026 exchanged $36.2 million (66.4% of outstanding) for new 11.00% Senior Secured Notes due July 1, 2027 plus cash. This constitutes creation of a new direct financial obligation—the issuance of new debt securities—and is material to investors assessing the company's capital structure and refinancing activity, particularly given the higher coupon rate and the timing relative to the original notes' maturity.
View raw filing on EDGAR →This is a clear earnings release disclosing Replimune's financial results for the fiscal fourth quarter and year ended March 31, 2026. The Item 2.02 filing includes a news release (Exhibit 99.1) announcing consolidated statements of operations, balance sheet data, and detailed financial metrics including R&D expenses ($221.2M), SG&A expenses ($98.7M), and net loss ($313.9M). The disclosure is material as it provides investors with comprehensive financial performance data for the fiscal year.
View raw filing on EDGAR →Professor Duncan Murray Campbell was appointed as a director of MDJM Ltd. for a two-year term, intended to strengthen the company's professional capabilities in cultural governance and strategy.
View raw filing on EDGAR →María Consuelo Loureiro Vilarello (Chelo Loureiro) was appointed as Chief Knowledge Officer of MDJM Ltd. for an initial two-year term pursuant to an employment agreement, bringing industry credentials expected to impact the company's animation and cultural strategy.
View raw filing on EDGAR →The 6-K discloses entry into a Securities Purchase Agreement on June 28, 2026, for the issuance of up to $10,000,000 in Senior Convertible Notes convertible into Class A ordinary shares. The notes were issued in a private placement under Section 4(a)(2) and Regulation D, with an initial closing of $2,000,000 on June 29, 2026. This is an unregistered sale of equity securities (convertible debt) that will dilute existing shareholders upon conversion, fitting the dilutive_issuance category. The materiality is clear given the size ($10M commitment, $2M initial) and the explicit disclosure of unregistered equity issuance.
View raw filing on EDGAR →Bit Origin announced the acquisition of approximately US$11 million in NVIDIA Blackwell B300 AI infrastructure assets, consisting of 16 servers with contracted customer deployment arrangements in Malaysia expected to generate US$360,000 in monthly recurring revenue. The transaction involves a material acquisition of revenue-generating assets (US$1 million cash + US$10 million in equity via pre-funded warrants) and represents a strategic expansion into AI computing infrastructure, marking the company's first Blackwell infrastructure transaction and a key milestone in its previously announced AI infrastructure strategy.
View raw filing on EDGAR →The Board of Trustees declared a distribution of $0.22 per Common Share for June 2026, payable on or around July 20, 2026, with a record date of June 30, 2026. This is a routine but material dividend distribution to shareholders, with the option to reinvest through the Fund's distribution reinvestment plan. As a closed-end fund, regular distributions are a core component of shareholder returns and material to investor assessment.
View raw filing on EDGAR →The Board appointed two new directors, David Endicott and Linnea Burman, effective June 29, 2026, increasing the Board size from nine to 11 members. Both appointments include full biographical details, independence determinations, and compensation arrangements.
View raw filing on EDGAR →This exhibit is a press release announcing iHuman Inc.'s unaudited financial results for the first quarter ended March 31, 2026. It discloses quarterly revenues (RMB182.5 million), gross profit, operating loss, and net income, along with key operational metrics (MAUs) and management commentary. The document explicitly states "iHuman Inc. Announces First Quarter 2026 Unaudited Financial Results" and includes detailed financial tables and forward-looking statements typical of an earnings release. While the results show declining revenues and a shift from operating income to operating loss year-over-year, the disclosure of quarterly financial results is a material event affecting investor assessment of the registrant's performance.
View raw filing on EDGAR →SOL Strategies announced the filing of "amended and restated" Q2 fiscal 2026 interim financial statements that "fully replace" the original filings from May 15, 2026. The company identified and corrected multiple presentation and classification matters including revaluation loss on digital assets, earnings per share, cash flow statements, shareholders' equity changes, fair value of cryptocurrencies, stock option activity, and subsequent events. Although the company states the corrections did not change total comprehensive loss, total assets, liabilities, or shareholders' equity, the restatement of interim financial statements is a material disclosure that would affect investor assessment of financial reporting reliability.
View raw filing on EDGAR →The Board declared a distribution of $0.430 per share payable to stockholders, representing an 8.8% annualized yield. This is a routine but material capital distribution to shareholders, fitting the dividend_distribution category. The disclosure includes the per-share amount, record date, and payment date—standard elements of a dividend announcement.
View raw filing on EDGAR →This is a comprehensive technical report on the Curipamba-El Domo polymetallic project in Ecuador, prepared by SRK Consulting for Silvercorp Metals Inc. The report contains mineral resource and reserve estimates, mining and processing plans, environmental assessments, and economic analysis. While technical reports are standard industry practice for mining projects, this document discloses material operational and strategic information about the project's development status, resource base, and economic viability that would be relevant to investors assessing the company's asset base and future production potential.
View raw filing on EDGAR →Union Electric Company (Ameren Missouri) issued $500 million principal amount of 5.75% First Mortgage Bonds due 2056, receiving net proceeds of approximately $492.2 million. This is a material creation of a direct financial obligation through debt issuance, clearly fitting the debt_issuance category. The substantial principal amount and long-term nature of the obligation make this material to investors.
View raw filing on EDGAR →The exhibit discloses the closing of a non-brokered private placement of 751,445 subscription receipts at US$1.73 per receipt for aggregate gross proceeds of approximately US$1,300,000. The subscription receipts will convert into common shares and warrants upon satisfaction of escrow release conditions tied to the Drayton International acquisition. This is a classic dilutive equity issuance that increases the share count and dilutes existing shareholders, with insider participation by the CFO, COO, and a director. The materiality is evident from the capital raised and the dilutive impact on ownership percentages.
View raw filing on EDGAR →The Company entered into a binding term sheet for the sale of 837 BTC (valued at $50 million) to Scilex Holding Company. While Item 1.01 typically covers M&A activity and material acquisitions/dispositions, this transaction is a cryptocurrency asset sale rather than a traditional business acquisition or merger. The sale is material (representing a significant asset disposition), but the nature—a direct asset sale of digital currency—fits more precisely under financial_other than ma_activity, which typically applies to business combinations or control changes. The substantial contingencies noted (need for definitive agreement, regulatory approvals, market conditions) and the deferred payment structure ($30M upfront, $20M over two years) underscore the transaction's financial significance.
View raw filing on EDGAR →Lucy Fato ceased to serve as Executive Vice President, General Counsel and Corporate Secretary effective June 25, 2026, with a final separation date of August 24, 2026. The disclosure centers on her departure from executive office and termination of employment "without cause," with associated severance payments and benefits. While she transitions to an advisory role through August, the principal disclosed action is the departure of a named executive officer from her officer positions.
View raw filing on EDGAR →The filing discloses entry into a "second amended and restated side letter" to the BANA Credit Facility on June 23, 2026, which modifies the minimum utilization level for calculating the unused commitment fee. This constitutes an amendment to an existing credit facility, a direct financial obligation. While the amendment appears technical in nature (adjusting fee calculation terms), amendments to material credit facilities are typically material to investors and fall under debt_issuance as the closest category for creation or modification of direct financial obligations.
View raw filing on EDGAR →The filing discloses entry into a "second amended and restated side letter" to the BANA Credit Facility, a revolving credit and security agreement. While this is technically an amendment rather than a new issuance, it modifies material terms of an existing direct financial obligation (the credit facility). The amendment to the minimum utilization level and unused commitment fee structure represents a modification of the credit facility's terms, which falls within the debt_issuance category's scope of "entry into or amendment of a credit facility." The materiality is supported by the fact that this is a material definitive agreement disclosed under Item 1.01.
View raw filing on EDGAR →The Company reduced the available sales capacity under its ATM (at-the-market) offering from an unspecified prior amount to $5 million and suspended the Sales Agreement Prospectus effective June 29, 2026. This represents a material reduction in the Company's access to capital markets and signals potential liquidity constraints or a shift in financing strategy. While not a traditional debt issuance or dilutive equity placement, this capital-raising modification is a financial event material to investor assessment of the registrant's liquidity position.
View raw filing on EDGAR →AeroVironment issued a press release on June 29, 2026 announcing fourth quarter and fiscal year 2026 financial results, including record revenue of $641.6 million for Q4 and $1,976.8 million for the full year (up 133% and 141% year-over-year respectively), net income of $63.2 million for Q4, and forward guidance for fiscal 2027.
View raw filing on EDGAR →Global Partners LP announced a full redemption of its Series B Fixed Rate Cumulative Redeemable Perpetual Preferred Units at $25.00 per unit plus accrued distributions, payable in cash on July 30, 2026. While redemption of preferred units is a capital transaction, it functions economically as a return of capital to preferred unitholders and is most closely aligned with dividend_distribution in the taxonomy. The redemption involves a cash payment to security holders and termination of their rights, which is material to investors holding or considering these securities.
View raw filing on EDGAR →Acura received three new loans totaling $400,000 from AD Pharma (May–June 2026) under an amended secured promissory note, bringing aggregate principal to $10.7 million as of June 24, 2026, with maturity extended to December 31, 2026. The company disclosed acute financial distress, stating that without additional financing by late July 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection.
View raw filing on EDGAR →The filing discloses termination of an at-the-market (ATM) offering agreement under Item 1.02. While the company had previously raised capital through this mechanism (2.775 million shares sold), the termination itself represents a change in the company's capital-raising capacity and signals a shift in financing strategy. This is material to investors assessing the registrant's access to capital markets, though it is not a new debt issuance, dilutive issuance, or other specifically-named financial event—hence financial_other rather than a more specific category.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Black Diamond Therapeutics' 2026 Annual Meeting held on June 26, 2026, filed under Item 5.07. The filing reports final voting tallies for four proposals: election of two Class III directors (Shannon Campbell and Kapil Dhingra), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and determination of voting frequency for future compensation advisory votes. The disclosure includes vote counts (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES) for each proposal, making this a textbook shareholder_vote_results event.
View raw filing on EDGAR →The disclosure announces FDA authorization of an Investigational New Drug (IND) application for GT-02287, enabling the company to initiate Phase 2 clinical development in Parkinson's disease. This is a material regulatory milestone in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, but does not fit the specific categories of earnings, M&A, impairment, litigation, or other named event types. It is clearly an operational/strategic business milestone.
View raw filing on EDGAR →Hertz Corp. completed an offering of $350 million aggregate principal amount of 6.75% Exchangeable Senior First-Lien Secured PIK Notes due 2030 pursuant to an Indenture dated June 29, 2026. This represents a material creation of a new direct financial obligation with specified interest rates, maturity date, exchange features, and covenants.
View raw filing on EDGAR →Hertz issued Exchangeable Notes in a private placement under Section 4(a)(2) and Rule 144A to qualified institutional buyers, with a maximum of 148.2 million shares of Common Stock potentially issuable upon exchange (or 169.4 million if the greenshoe is exercised). This unregistered offering of convertible securities materially affects shareholder equity and voting power.
View raw filing on EDGAR →Hertz entered into an underwriting agreement on June 24, 2026 for the public offering of 37,037,037 shares of Common Stock at $2.70 per share, with shares loaned to J.P. Morgan Securities LLC under a share lending agreement. This registered public offering on Form S-3 represents a material equity issuance that dilutes existing shareholders.
View raw filing on EDGAR →Cogent Communications completed the sale of 10 data center facilities to an I Squared Capital affiliate for $225 million in cash on June 29, 2026. This is a material disposition of assets—a significant divestiture of operating facilities that would affect a reasonable investor's assessment of the company's asset base, revenue-generating capacity, and capital structure. The transaction was previously announced and closed on the filing date, making this a completion of a material M&A activity.
View raw filing on EDGAR →United Therapeutics held its Annual Meeting of Shareholders on June 26, 2026, with shareholders voting on four matters: election of 11 directors, advisory vote on executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of Ernst & Young LLP as independent auditor. The filing discloses the detailed vote tallies for each matter.
View raw filing on EDGAR →Liberty Capital Corp entered into Amendment No. 1 to its Credit Agreement on June 29, 2026, adding $455 million in new incremental debt facilities comprising a $155 million delayed draw Term A-1 Loan, a $300 million Term A-2 Loan, and a $25 million incremental revolving L/C facility, all secured by substantially all assets of GCI and its subsidiaries.
View raw filing on EDGAR →TopBuild stockholders voted on June 29, 2026 to approve the merger agreement with QXO, with approximately 78% of votes cast (65% of outstanding shares) voting in favor of the TopBuild Merger Proposal.
View raw filing on EDGAR →QXO and TopBuild stockholders voted on the proposed acquisition on June 29, 2026. QXO stockholders approved the issuance of QXO common stock as consideration (~99% in favor) and a charter amendment to increase authorized shares from 2 billion to 4 billion (~99.2% in favor); TopBuild stockholders approved the merger agreement (78% of votes cast, 65% of outstanding shares).
View raw filing on EDGAR →FS KKR Capital Corp. issued and sold 6,000,000 shares of Cumulative Convertible Perpetual Preferred Stock to KKR Alternative Assets L.P. for $150 million on June 29, 2026. The convertible preferred stock is convertible into common stock at an initial conversion price of $18.83 per share, creating material dilution potential for existing common shareholders.
View raw filing on EDGAR →The company's investment adviser waived 50% of subordinated income incentive fees for four fiscal quarters (Q2 2026 through Q1 2027) with no recoupment rights, materially reducing the company's operating costs during the waiver period.
View raw filing on EDGAR →The filing discloses compensatory arrangements for three named executives: salary increases (retroactive to April 1, 2026) for Serhii Kupriienko (CEO Global) from $250,000 to $375,000, Alexander Fink (CEO U.S. and President) from $250,000 to $375,000, and Brooks Ensign (CFO) from $250,000 to $300,000, along with target annual bonuses of 100%, 100%, and 50% of base salary respectively. These are material changes to executive compensation approved by the Compensation Committee and Board.
View raw filing on EDGAR →This Item 7.01 disclosure concerns the proposed business combination between Spring Valley Acquisition Corp. III (SVAC) and General Fusion Inc., which was previously disclosed in an 8-K filed January 23, 2026. The filing furnishes an updated investor presentation (Exhibit 99.1) for use in shareholder presentations. The disclosure references the Business Combination Agreement, the effective Registration Statement on Form F-4 (declared effective June 12, 2026), and the definitive Proxy Statement filed June 15, 2026 for shareholder voting. This is a material acquisition/change-of-control transaction in the advanced stages of completion, with shareholder voting imminent.
View raw filing on EDGAR →Angel Studios entered into amended and restated merger agreements on June 29, 2026 to acquire two production companies: Tuttle Twins Show, LLC and Toothy Cow Productions, LLC. The filing discloses material revisions to previously disclosed merger agreements, including extended closing dates (October 31, 2026), modified closing conditions, and clarified consideration structures. The Company has already committed $11.7 million in operational funding to TTS and $11.9 million to TCP, with significant insider ownership stakes (41.6% of TTS units and 2.4% of TCP units held by Company-related parties). These are material acquisition transactions that would substantially affect the registrant's business and financial position.
View raw filing on EDGAR →Versamet Royalties Corp held its Annual General and Special Meeting of Shareholders on June 29, 2026, with shareholders voting on and approving four matters: appointment of PricewaterhouseCoopers LLP as auditors, election of eight directors, approval of amendments to the company's articles, and approval of amendments to the omnibus equity incentive plan.
View raw filing on EDGAR →Realty Income Corporation entered into a purchase agreement to issue and sell €600.0 million aggregate principal amount of 3.625% Notes due 2032 to underwriters led by Barclays Bank PLC, BNP PARIBAS, RBC Europe Limited, Banco Santander, and Wells Fargo Securities International Limited, with anticipated closing on July 7, 2026. This is a material debt issuance creating a new direct financial obligation.
View raw filing on EDGAR →The exhibit announces approval of material amendments to the Company's 9.875% senior secured bonds (US$150.0 million nominal), including release of ship mortgages converting the bonds from secured to unsecured, removal of use-of-proceeds restrictions, and an increase in the minimum liquidity covenant from US$20.0 million to US$30.0 million. While technically an amendment rather than a new issuance, the restructuring materially alters the Company's direct financial obligations and capital structure, warranting classification as a debt-related event. The amendment fee of 0.325% and the shift from secured to unsecured status are material to investors assessing the Company's leverage and creditworthiness.
View raw filing on EDGAR →The Fund priced and is issuing $400 million in aggregate principal amount of 6.500% Notes due 2031 in a private placement. This is a creation of a new direct financial obligation—a debt issuance—which is material to investors as it represents a significant capital raise and increases the Fund's leverage. The disclosure explicitly states the offering price, maturity date, interest rate, and expected closing date, all hallmarks of a debt issuance event under Item 2.03 (or disclosed here under Item 8.01).
View raw filing on EDGAR →This press release announces FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, a regulatory milestone that accelerates development and review timelines. While not a discrete M&A, financing, or personnel event, the Fast Track designation—combined with existing Orphan Drug and Rare Pediatric Disease designations—materially advances the clinical program's regulatory pathway and represents a significant operational/strategic achievement for a clinical-stage biotech company. The designation is material to investors assessing the company's progress toward commercialization.
View raw filing on EDGAR →BioCryst's Board approved a plan on June 25, 2026 to discontinue internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence facility by end of 2026, involving employee termination benefits, severance, and a strategic shift toward external innovation. The restructuring resulted in improved 2026 non-GAAP operating expense guidance from $450–$470M to $420–$440M.
View raw filing on EDGAR →This is an announcement of Golar LNG's Q2 2026 financial results release scheduled for August 13, 2026, with details on how to access the webcast presentation and conference call. Although the exhibit itself is a procedural notice rather than the results document itself, it announces the imminent disclosure of quarterly financial results, which is a material event that would affect investor assessment of the registrant's financial performance and position.
View raw filing on EDGAR →This press release announces positive real-world clinical data from a 462-patient study showing 83.5% response rate in comorbid PTSD and MDD patients treated with Deep TMS. While the data is preliminary and not yet FDA-cleared for these indications, the announcement of significant clinical evidence supporting the company's core product platform in a large patient population represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline and commercial prospects. The study is the "largest real-world analysis" to date in this patient population, strengthening the clinical evidence base for the company's technology.
View raw filing on EDGAR →This is a transparency notification disclosing that Madison Avenue Partners crossed the 5% voting-rights threshold in Lakefront Biotherapeutics on June 15, 2026, acquiring 3,498,892 voting rights (5.31% of outstanding shares). While not a traditional governance event like an executive appointment or board change, this is a material shareholder disclosure under Belgian transparency legislation that would affect a reasonable investor's assessment of ownership structure and potential control dynamics. The event is governance-related (shareholder notification) but does not fit the specific named categories, making `governance_other` the appropriate classification.
View raw filing on EDGAR →The filing announces receipt of $43 million in additional orders for Sidewinder ESA terminals from a major in-flight connectivity service provider, with deliveries planned over 18 months. This represents a material operational and commercial milestone—a significant customer order that validates product demand and supports business growth—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). The order is material to a reasonable investor assessing the registrant's revenue trajectory and market position.
View raw filing on EDGAR →RedHill Biopharma filed a prospectus supplement on June 29, 2026 to increase the maximum aggregate offering amount of American Depositary Shares under an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. An ATM offering is an unregistered or registered equity issuance program that allows continuous sale of shares at market prices, which is dilutive to existing shareholders. This is a material capital-raising event typical of small- and mid-cap biotech companies.
View raw filing on EDGAR →